Axsome Therapeutics, Inc. (AXSM)
$
104.64
+1.65 (1.58%)
Key metrics
Financial statements
Free cash flow per share
-2.4196
Market cap
5.2 Billion
Price to sales ratio
11.9708
Debt to equity
3.9360
Current ratio
2.0279
Income quality
0.4252
Average inventory
16 Million
ROE
-3.6379
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders within the United States. The company's product pipeline features AXS-05, which is intended for treating major depressive disorder and resistant depression disorders. Currently, AXS-05 is undergoing a Phase III clinical trial aimed at addressing agitation associated with Alzheimer's disease and has also completed a Phase II clinical trial related to smoking cessation. Additionally, Axsome is advancing AXS-07, a novel, oral medication known for its rapid absorption and multi-mechanistic approach, having completed two Phase III trials for acute migraine treatment. AXS-12 is another investigational product, a selective and potent norepinephrine reuptake inhibitor currently in Phase III trials for narcolepsy treatment, while AXS-14, an oral investigational drug, is also in Phase III for fibromyalgia. Moreover, Axsome Therapeutics has established a research collaboration with Duke University to evaluate the efficacy of AXS-05 in smoking cessation. The company has shown significant financial growth, as evidenced by the recorded revenue of $385,693,000.00 demonstrating a steady upward trajectory. The income before tax ratio is -0.74 reflecting the pre-tax margin, while the net income ratio stands at -0.74 indicating the company's profitability margin. However, operating expenses amount to $632,952,000.00 which encompass various costs incurred for operations. Overall, the total costs and expenses for the company reach $666,255,000.00 illustrating its comprehensive spending in pursuit of its goals. In the context of market performance, Axsome Therapeutics' stock is reasonably priced at $102.99 making it attractive to a diverse range of investors. Despite this, the stock has a low average trading volume of 697,912.00 signaling a lower level of market activity. The company maintains a mid-range market capitalization of $5,152,096,896.00 positioning it as a steady performer within the industry. As a key player in the Biotechnology industry, Axsome Therapeutics contributes significantly to the broader market landscape, reinforcing its relevance and impact. Additionally, it belongs to the Healthcare sector, driving both innovation and growth in the field, thereby ensuring its sustained presence in an evolving market.
Is Axsome Therapeutics, Inc. (AXSM) a good investment?
Investing in Axsome Therapeutics, Inc. (AXSM) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Axsome Therapeutics, Inc. (AXSM)'s stock forecast?
Analysts predict Axsome Therapeutics, Inc. stock to fluctuate between $64.11 (low) and $139.13 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Axsome Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Axsome Therapeutics, Inc.'s market cap is $5,152,096,896, based on 49,236,400 outstanding shares.
How does Axsome Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Axsome Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Axsome Therapeutics, Inc. (AXSM) stock?
To buy Axsome Therapeutics, Inc. (AXSM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AXSM. Place an order (Market, Limit, etc.).
What is the best time to invest in Axsome Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Axsome Therapeutics, Inc. perform in the last earnings report?
Revenue: $385,693,000 | EPS: -$5.99 | Growth: 13.66%.
Where can I find Axsome Therapeutics, Inc.'s investor relations reports?
Visit https://www.axsome.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Axsome Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Axsome Therapeutics, Inc. stock?
All-time high: $139.13 (2025-02-21) | All-time low: $19.38 (2021-08-19).
What are the key trends affecting Axsome Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fool.com
Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
fool.com
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
zacks.com
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
seekingalpha.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Graig Suvannavejh - Mizuho Securities Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Troy Langford - TD Cowen Ami Fadia - Needham & Company Operator Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast.
zacks.com
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
zacks.com
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
zacks.com
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
zacks.com
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
See all news
